Current concept of the role of monocytes/macrophages in inflammatory bowel disease - balance of proinflammatory and immunosuppressive mediators

Italian Journal of Gastroenterology and Hepatology

Volumn 30, Issue 3, 1998, Pages 338-344

  Lugering N ^a   Kucharzik, T ^a   Stoll, R ^a   Domschke, W ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

27E10; IBD; Monocytes macrophages; MRP14; MRP8; TH2 cytokines

Indexed keywords

CALCIUM BINDING PROTEIN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4;

COLON MUCOSA; DISEASE ACTIVITY; DRUG POTENTIATION; ENTERITIS; HELPER CELL; HUMAN; HUMAN CELL; ILEUM; INFLAMMATORY INFILTRATE; INTESTINE EPITHELIUM; INTESTINE MUCOSA; INTESTINE ULCER; MACROPHAGE; MACROPHAGE FUNCTION; MONOCYTE; PROTEIN SECRETION; REVIEW;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; MACROPHAGES; MONOCYTES;

EID: 0031829346     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Allison MC, Poulter LW. Changes in phenotypically distinct mucosal macrophage populations may be a prerequisite for the development of inflammatory bowel disease. Clin Exp Immunol 1991;85:504-9.
2. Selby WS, Janossy G, Mason DY, Jewell DP. Expression of HLA-DR antigens by colonie epithelium in inflammatory bowel disease. Clin Exp Immunol 1983;53:614-8.
3. Selby WS, Poulter LW, Hobbs S, Jewell DP, Janossy G. Heterogeneity of HLA-DR-positive histiocytes in human intestinal lamina propria: a combined histochemical and immunohistological analysis. J Clin Pathol 1983;36:379-84.
4. Hume DA, Allan W, Hogan PG, Doe WE Immunohistochemical characterization of macrophages in human liver and gastrointestinal tract: Expression of CD4, HLA-DR, OKM1, and the mature macrophage marker 25F9 in normal and diseased tissue. J Leuk Biol 1987;42:474-84.
5. Mahida YR, Patel S, Gionchetti P, Vaux D, Jewell DP. Macrophage subpopulations in lamina propria of normal and inflamed colon and terminal ileum: Gut 1989;30:826-34.
6. Choy MY, Walker-Smith JA, Williams CB, MacDonald TT. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 1990;31:1365-70.
7. Seldenrijk CA, Drexhage HA, Meuwissen SGM, Pals ST, Meijer CJ. Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease. Gut 1989;30:484-91.
8. Saverymuttu SH, Peters AM, Lavender JP, Pepys MB, Hodgson HJ, Chadwick VS. Quantitative fecal indium Ill-labeled leucocyte excretion in the assessment of disease activity in Crohn's disease. Gastroenterology 1983 ;85:1333-9.
9. Saverymuttu SH, Peters AM, Lavender JP, Chadwick VS, Lavender JR. In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease. Gut 1985;26:378-83.
10. Lügering N, Stoll R, Holzgreve A, Winde G, Sorg C, Domschke W. Monoclonal antibody 1F10 immunoreactivity in inflammatory bowel disease: a new marker specific only for continuous endothelial cells. Eur J Gastroenterol Hepatol 1995;7:777-81.
11. Malizia G, Calabrese A, Cottone M, Raimondo M, Trejdosiewics LK, Smart CJ, et al. Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology 1991; 100:150-9.
12. Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992;103:840-7.
13. Rugtveit J, Brandtzaeg P, Halstensen T, Fausa O, Scott H. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994;35:669-74.
14. Rugtveit J, Haraldsen G, Hogasen AK, Bakka A, Brandtzaeg P, Scott H. Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells. Gut 1995;37:367-73.
15. Bhardwaj RS, Zotz C, Zwadlo-Klarwasser G, Roth J, Gocbeler M, Mahnke K, et al. The calcium-binding proteins MRP8 and MRP14 form a membrane associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions. Eur J Immunol 1992;22:1891-7.
16. Schmid KW, Lügering N, Stoll R, Brinkbäumer P, Winde G, Domschke W, et al. Immunohistochemical demonstration of the calcium-binding proteins MRP8 and MRP14 and their heterodimer (27E10 antigen) in Crohn's disease. Hum Pathol 1995;26:334-7.
17. Lügering N, Stoll R, Schmid KW, Kucharzik T, Stein H, Burmeister G, et al. The myeloic related protein MRP8/14 (27E10 antigen) - usefulness as a potential marker for disease activity in ulcerative colitis and putative biological function. Eur J Clin Invest 1995;25:659-64.
18. Odink K, Cerletti N, Briiggen J, Clerc RG, Tarcsay L, Zvvadlo G, et al. Two calcium-binding proteins in infiltrating macrophages of rheumatoid arthritis. Nature 1987;330:80-2.
19. Lügering N, Stoll R, Kucharzik T, Schmid KW, Rohlmann G, Burmeister G, et al. Immunohistochemical distribution and sérum levels of the Ça2-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease. Digestion 1995;56:406-14.
20. Roth J, Burwinkel F, van den Bos C, Goebeler M, Vollmer E, Sorg C. MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. Blood 1993;82:1875-83.
21. Roth J, Goebeler M, Wrocklage V, van den Bos C, Sorg C. Expression of the calcium-binding proteins MRP8 and MRP14 in monocytes is regulated by a calcium-induced suppressor mechanism. Biochem J 1994;301:655-60.
22. Steinbakk M, Naess-Andersen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leukocyte LI protein, calprotectin. Lancet 1990;336:763-5.
23. Murao S, Collait FR, Huberman E. A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. J Biol Chem 1989;264:8356-60.
24. Zwadlo G, Schlegel R, Sorg C. A monoclonal antibody to a subset of human monocytes found only in the peripheral blood and inflammatory tissues. J Immunol 1986;137:512-8.
25. Zwadlo G, Briiggen J, Gerhards G, Schlegel R, Sorg C. Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues. Clin Exp Immunol 1988;72:510-5.
26. Roth J, Teigelkamp St, Wilke M, Grün L, Tümmler B, Sorg C. Complex pattern of the myelomonocytic differentiation antigens MRP8 and MRP14 during chronic airway inflammation. Immunbiol 1992;186:304-14.
27. Goebeler M, Roth J, van den Bos C, Ader G, Sorg C. Increase of calcium levels in epithelial cells induces translocation of calciumbinding proteins migration inhibitory factor-related protein 8 (MRP8) and MRP14 to keratin intermediate filaments. Biochem J 1995;309:419-24.
28. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte J, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. J Immunol 1996;157:1261-70.
29. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994;106:533-9.
30. Reimund JM, Duclos B, Sapin R, Derlon A, Chamourard P, Baumann R. Systemic tumour necrosis factor in Crohn's disease: relationship to disease activity and circulating acute phase reactants. Eur J Gastroenterol Hepatol 1992;4:919-23.
31. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
32. Mazlam MZ, Hodgson HJF. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992;33:773-8.
33. Reinecker HC, Steffen M, Witthoeft T, Pfleuger I, Schreiber S, McDermott RP, et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993:94:174-81.
34. Reimund JM, Wittersheim C, Dumont S, Muller CD, Baumann R, Poindron P, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996:16:144-50.
35. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, et al. Increased production of tumour necrosis factor-a, interleukin-β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996:39:684-9.
36. Kucharzik T, Lügering N, Weigelt H, Adolf M, Domschke W, Stoll R. Immunoregulatory properties of Interleukin-13 in patients with inflammatory bowel disease. Comparison with Interleukin-4 and Interleukin-10. Clin Exp Immunol 1996; 104:483-90.
37. Isaacs KL, Sartor RB, Haeskil JS. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
38. MacDonald TT, Mulchings P, Choy MY, Murch S, Cooke A. Tumor necrosis factor-alpha and interferon-gamma production measured at the single-cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
39. Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat GNJ, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993:342:173-4.
40. Van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995:109:129-35.
41. Targan S, Rutgeerts P, Hanauer SB, van Deventer HJS, Mayer L, Present DH, et al. A multicenter trial of anti-tumor necrosis factor (TNF) antibody (cA2) for treatment of patients with active Crohn's disease. Gastroenterology 1996;110:1026A.
42. Cominelli F, Dinarello CA. Interleukin-1 in the pathogenesis of and protection from inflammatory bowel disease. Biotherapy 1989:1:369-75.
43. Cominelli F, Nast CC, Clark BD. Interleukin-1 (IL-1) gene expression, synthesis and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990:86:972-80.
44. Mahida, YR, Wu K, Jewell DP. Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disesase. Gut 1989:30:1362-70.
45. Baldassano RN, Schreiber S, Johnston RB, Muraki T, MacDermott RP. Monocytes of patients with Crohn's disease are primed for accentuated release of toxic oxygen metabolites: possible role for endotoxin. Gastroenterology 1993:105:60-6.
46. Ganguly N, Lloyd B, Price C, Kingham J, Lloyd R, Triger D. Acid hydrolases in monocytes from patients with inflammatory bowel disease, chronic liver disease and rheumatoid arthritis. Lancet 1978;i: 1073-5.
47. Mee AS, Szawatakowski M, Jewell DP. Monocytes in inflammatory bowel disease: phagocytosis and intracellular killing. J Clin Pathol 1980:33:921-5.
48. Mee AS, Jewell DP. Monocytes in inflammatory bowel disease: monocyte and serum lysosomal enzyme activity. Clin Sei 1980;58:295-300.
49. Lügering N, Kucharzik T, Stein H, Winde G, Hasilik A, Domschke W, et al. IL-10 synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease. Dig Dis Sei 1998;43:706-14.
50. Fiorentino DF, Zlotnik A, Vieira P, Mosman TR, Howard M, Moore KVV, et al. IL-10 acts on the antigen presenting cells to inhibit cytokine production by Thl cells. J Immunol 1991;146:3444-51.
51. Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992;148:3133-9.
52. Casatella MA, Meda L, Gasperini S, Calzetti F, Bonora S. Interleukin-10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994:179:1695-9.
53. Hart PH, Jones CA, Finlay-Jones JJ. Monocytes cultured in cytokine-defined environments differ from freshly isolated monocytes in their responses to IL-4 and IL-10. J Leuk Biol 1995;57:909-18.
54. Buelens C, Willems F, Delvaux A, Pierard G, Delville JP, Velu T, et al. Interleukin-10 differentially regulates B7-1 (CD80) and B72 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995;25:2688-72.
55. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995;108:1434-44.
56. Kucharzik T, Stoll R, Lügering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 100:452-6.
57. Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, Sartor RB. Interleukin-10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996;39:836-45.
58. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-defïcient mice develop chronic enterocolitis. Cell 1993;75:263-74.
59. Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Stahl PD, et al. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995;108:21-33.
60. West GA, Matsuura T, Levine AD, Klein IS, Fiocchi C. Interleukin-4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology 1996; 110:1683-95.
61. Kucharzik T, Lügering N, Adolf M, Domschke W, Stoll R. Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease. Dig Dis Sei 1997;42;805-12.
62. Lügering N, Kucharzik T, Winde G, Sorg C, Domschke W, Stoll R. Importance of combined treatment with IL-10 and IL-4, but not IL-13, for inhibiting monocyte release of the Ca2+-binding protein MRP8/14. Immunology 1997;91;130-4.